A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

ECO-RESET: A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE DOSE, MULTICENTER STUDY TO ASSESS EFFICACY AND SAFETY OF SER-287 IN ADULTS WITH ACTIVE MILD-TO-MODERATE ULCERATIVE COLITIS

Intervention/treatment:
SER-287/VANCOMYCIN HYDROCHLORIDE (OVER ENCAPSULATED)
Medical condition:
ULCERATIVE COLITIS
Protocol code:
SERES-201
Control number:
223072
Status:
Closed
Approved:
January 16, 2019
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT03759041
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 80 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Lisa von Moltke, MD, Chief Medical Officer
Organization
Seres Therapeutics
Phone:
617-945-9626
Sponsor
SERES THERAPEUTICS

Locations

Alberta

(Investigator site)
Edmonton, Alberta, T6G 2L7
(Investigator site)
Edmonton, Alberta, T6L 6K3

British Columbia

(Investigator site)
New Westminster, British Columbia, V3L 3W4

Ontario

(Investigator site)
Bridgewater, Ontario, B4V 3K9
(Investigator site)
Greater Sudbury, Ontario, P3C 5K6
(Investigator site)
Lindsay, Ontario, K9V 5G6
(Investigator site)
London, Ontario, N6A 5A5
(Investigator site)
London, Ontario, N6A 5W9
(Investigator site)
Toronto, Ontario, M5T 3A9
(Investigator site)
Vaughan, Ontario, L4L 4Y7

Quebec

(Investigator site)
Greenfield Park, Quebec, J4V 2H1

Saskatchewan

(Investigator site)
Saskatoon, Saskatchewan, S7N 0W8

Results

See the results from the trial NCT03759041. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?